Página principal > Artículos > Resultados de la búsqueda: Neoplasms

Artículos

  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Artículos Encontrados 106 registros  anterior11 - 20siguientefinal  ir al registro: La búsqueda tardó 0.00 segundos. 
11.
6 p, 255.0 KB Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer : Supporting personalised screening / Román, M. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Quintana Ruiz, Maria Jesús (Institut d'Investigació Biomèdica Sant Pau) ; Ferrer, J. (Parc Hospitalari Martí i Julià) ; Sala, M. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Castells, X. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Universitat Autònoma de Barcelona
Our aim was to assess the cumulative risk of false-positive screening results, screen-detected cancer, and interval breast cancer in mammography screening among women with and without a previous benign breast disease and a family history of breast cancer. [...]
2017 - 10.1038/bjc.2017.107
British Journal of Cancer, Vol. 116 Núm. 11 (23 2017) , p. 1480-1485  
Registro completo - Creative Commons
12.
11 p, 1.3 MB Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools / García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Martínez Jiménez, Francisco (Institute for Research in Biomedicine (IRB Barcelona)) ; Valencia, Alfonso (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Porta-Pardo, Eduard (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Motivation: The analysis of cancer genomes provides fundamental information about its etiology, the processes driving cell transformation or potential treatments. While researchers and clinicians are often only interested in the identification of oncogenic mutations, actionable variants or mutational signatures, the first crucial step in the analysis of any tumor genome is the identification of somatic variants in cancer cells (i. [...]
2022 - 10.1093/bioinformatics/btac306
Bioinformatics, Vol. 38 Núm. 12 (15 2022) , p. 3181-3191  
Registro completo - Creative Commons
13.
11 p, 1.2 MB Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma / Madariaga, Ainhoa (Universitat Autònoma de Barcelona) ; Garg, Swati (University Health Network, Toronto, Canada) ; Tchrakian, Nairi (University Health Network, Toronto, Canada) ; Dhani, Neesha C. (University of Toronto, Canada) ; Jimenez, Waldo (Juravinski Cancer Centre, Hamilton, Canada) ; Welch, Stephen (London Health Sciences Center, London, Canada) ; MacKay, Helen (Odette Cancer Centre. Sunnybrook Health Sciences Centre, Toronto, Canada) ; Ethier, Josee-Lyne (Kingston Health Sciences Cancer Centre, Kingston, Canada) ; Gilbert, Lucy (Royal Victoria Hospital, Montréal, Canada) ; Li, Xuan (University Health Network, Toronto, Canada) ; Rodriguez, Angela (University Health Network, Toronto, Canada) ; Chan, Lucy (University Health Network, Toronto, Canada) ; Bowering, Valerie (University Health Network, Toronto, Canada) ; Clarke, Blaise (University Health Network, Toronto, Canada) ; Zhang, Tong (University of Toronto, Canada) ; King, Ian (University of Toronto, Canada) ; Downs, Gregory (University of Toronto, Canada) ; Stockley, Tracy (University of Toronto, Canada) ; Wang, Lisa (University of Toronto, Toronto, Canada) ; Udagani, Smitha (University Health Network, Toronto, Canada) ; Oza, Amit M. (University of Toronto, Canada) ; Lheureux, Stephanie (University of Toronto, Canada)
This multi-centre, non-randomized, open-label, phase II trial (NCT03016338), assessed niraparib monotherapy (cohort 1, C1), or niraparib and dostarlimab (cohort 2, C2) in patients with recurrent serous or endometrioid endometrial carcinoma. [...]
2023 - 10.1038/s41467-023-37084-w
Nature communications, Vol. 14 (2023) , art. 1452  
Registro completo - Creative Commons
14.
25 p, 1.7 MB Analysis of the Clinical Relevance of Histological Classification of Benign Epithelial Salivary Gland Tumours / Hellquist, Henrik (University of Algarve) ; Paiva-Correia, António (Manchester University NHS Foundation Trust) ; Vander Poorten, Vincent (Multidisciplinary Salivary Gland Society) ; Quer, Miquel (Institut d'Investigació Biomèdica Sant Pau) ; Hernandez-Prera, Juan C. (Moffitt Cancer Center) ; Andreasen, Simon (Zealand University Hospital) ; Zbären, Peter (University Hospital) ; Skalova, Alena (Charles University) ; Rinaldo, Alessandra (University of Udine School of Medicine) ; Ferlito, Alfio (International Head and Neck Scientific Group) ; Universitat Autònoma de Barcelona
A vast increase in knowledge of numerous aspects of malignant salivary gland tumours has emerged during the last decade and, for several reasons, this has not been the case in benign epithelial salivary gland tumours. [...]
2019 - 10.1007/s12325-019-01007-3
Advances in Therapy, Vol. 36 Núm. 8 (january 2019) , p. 1950-1974  
Registro completo - Creative Commons
15.
11 p, 987.9 KB Participants' satisfaction with colorectal cancer screening programs : A systematic review / Selva, A. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Mosconi, Giansanto (University of Pavia) ; Cacitti, Stefano (Health Protection Agency of Pavia) ; Odone, Anna (University of Pavia) ; Pylkkanen, Liisa (University of Turku) ; Solà, Ivan (Institut d'Investigació Biomèdica Sant Pau) ; Torà, Núria (Althaia Xarxa Assistencial Universitària de Manresa) ; Russo, Sara (University of Pavia) ; Cadum, Ennio (Health Protection Agency of Pavia) ; Deandrea, Silvia (Health Protection Agency of Pavia) ; Universitat Autònoma de Barcelona
Since satisfaction with cancer screening experience can increase adherence to programs and contribute to reduce morbidity and mortality, its assessment is crucial for programs' effectiveness. Our aim was to conduct a systematic review about satisfaction of participants with organized colorectal cancer screening. [...]
2023 - 10.1016/j.ypmed.2023.107706
Preventive Medicine, Vol. 175 (october 2023) , p. 107706  
Registro completo - Creative Commons
16.
10 p, 1.1 MB Monitoring and evaluation of breast cancer screening programmes : Selecting candidate performance indicators / Muratov, Sergei (McMaster University (Canadà)) ; Canelo Aybar, Carlos Gilberto (Institut d'Investigació Biomèdica Sant Pau) ; Tarride, Jean-Eric (McMaster University (Canadà)) ; Alonso-Coello, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Dimitrova, Nadya (Joint Research Centre) ; Borisch, Bettina (University of Geneva) ; Castells, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ; Duffy, Stephen W. (Queen Mary University of London) ; Fitzpatrick, Patricia (UCD School of Public Health) ; Follmann, Markus (German Cancer Society) ; Giordano, Livia (CPO-Piedmont - AOU Città della Salute e della Scienza) ; Hofvind, Solveig (Cancer Registry of Norway) ; Lebeau, Annette (University Medical Center Hamburg-Eppendorf) ; Quinn, Cecily (Ordensklinikum Linz Elisabethinen) ; Torresin, Alberto (ASST Grande Ospedale Metropolitano) ; Vialli, Claudia (Joint Research Centre) ; Siesling, Sabine (University of Twente) ; Ponti, Antonio (CPO-Piedmont - AOU Città della Salute e della Scienza) ; Giorgi Rossi, Paolo (Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia (Itàlia)) ; Schünemann, Holger (McMaster University (Canadà)) ; Nyström, Lennarth (Umeå University) ; Broeders, Mireille (Radboud University Medical Center) ; Autelitano, Mariangela ; Colzani, Edoardo ; Daneš, Jan ; Gräwingholt, Axel ; Ioannidou-Mouzaka, Lydia ; Knox, Susan ; Langendam, Miranda ; McGarrigle, Helen ; Pérez Gómez, Elsa ; Van Engen, Ruben ; Warman, Sue ; Young, Kenneth ; Van Landsveld-Verhoeven, Cary ; Lerda, Donata ; Saz-Parkinson, Zuleika ; Parmelli, Elena ; Janusch-Roi, Annett ; Universitat Autònoma de Barcelona
In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. [...]
2020 - 10.1186/s12885-020-07289-z
BMC Cancer, Vol. 20 Núm. 1 (24 2020) , p. 795  
Registro completo - Creative Commons
17.
5 p, 148.2 KB Diagnostic accuracy of salivary biomarkers for oral cancer and potentially malignant disorders : A systematic review protocol Precisión diagnóstica de biomarcadores salivales para cáncer oral y desórdenes potencialmente malignos: protocolo de revisión sistemática / Madera, Meisser (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Ariel Franco, J.V. (Instituto Universitario Hospital Italiano) ; Solà, Ivan (Institut d'Investigació Biomèdica Sant Pau) ; Bonfill, X. (Xavier) (Institut d'Investigació Biomèdica Sant Pau) ; Arevalo-Rodriguez, Ingrid (Hospital Universitario Ramón y Cajal (Madrid)) ; Universitat Autònoma de Barcelona
Oral cancer has a 5-year survival rate of 50% because diagnosis is commonly performed at an advanced stage of the disease, so new diagnostic tools are needed. Nowadays, there is a vast number of publications suggesting the use of salivary biomarkers for oral cancer and potentially malignant disorders diagnosis, but their diagnostic accuracy is unclear. [...]
2020 - 10.5867/medwave.2020.05.7938
Medwave, Vol. 20 Núm. 5 (junio 2020) , p. e7938  
Registro completo - Creative Commons
18.
20 p, 1.6 MB Healthcare providers' adherence to breast cancer guidelines in Europe : a systematic literature review / Niño de Guzmán, Ena Pery (Institut d'Investigació Biomèdica Sant Pau) ; Song, Yang (Institut d'Investigació Biomèdica Sant Pau) ; Alonso-Coello, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Canelo Aybar, Carlos Gilberto (Institut d'Investigació Biomèdica Sant Pau) ; Neamtiu, L. (Joint Research Centre (JRC)) ; Parmelli, Elena (European Commission. Joint Research Centre (JRC)) ; Pérez-Bracchiglione, J. (Universidad de Valparaíso) ; Rabassa Bonet, Montserrat (Institut d'Investigació Biomèdica Sant Pau) ; Rigau, David (Institut d'Investigació Biomèdica Sant Pau) ; Parkinson, Z.S. (Joint Research Centre (JRC)) ; Solà, Ivan (Institut d'Investigació Biomèdica Sant Pau) ; Vásquez-Mejía, A. (Universidad Nacional Mayor de San Marcos (Lima, Perú)) ; Ricci-Cabello, I. (Balearic Islands Health Service) ; Universitat Autònoma de Barcelona
Clinical guidelines' (CGs) adherence supports high-quality care. However, healthcare providers do not always comply with CGs recommendations. This systematic literature review aims to assess the extent of healthcare providers' adherence to breast cancer CGs in Europe and to identify the factors that impact on healthcare providers' adherence. [...]
2020 - 10.1007/s10549-020-05657-8
Breast Cancer Research and Treatment, Vol. 181 Núm. 3 (january 2020) , p. 499-518  
Registro completo - Creative Commons
19.
14 p, 2.0 MB Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer / Angeles, Martina Aida (Institut Universitaire du Cancer de Toulouse Oncopole) ; Cabarrou, Bastien (Institut Universitaire du Cancer de Toulouse Oncopole) ; Gil-Moreno, Antonio 1965- (Vall d'Hebron Institut d'Oncologia) ; Pérez-Benavente, Assumpció (Vall d'Hebron Institut d'Oncologia) ; Spagnolo, Emanuela (Hospital Universitario La Paz (Madrid)) ; Rychlik, Agnieszka (Department of Gynaecologic Oncology, Maria Skłodowska-Curie National Research Institute of Oncology) ; Martínez-Gómez, Carlos (INSERM CRCT 1 (França)) ; Guyon, Frédéric (Department of Surgical Oncology, Institut Bergonié (França)) ; Zapardiel, Ignacio (Hospital Universitario La Paz (Madrid)) ; Querleu, Denis (Honorary Professor of the University of Toulouse) ; Illac, Claire (Institut Universitaire du Cancer de Toulouse Oncopole) ; Migliorelli, Federico (Department of Gynaecology and Obstetrics, Centre Hospitalier Intercommunal des Vallées de l'Ariège (França)) ; Bétrian, Sarah (Institut Universitaire du Cancer de Toulouse Oncopole) ; Ferron, Gwénaël (INSERM CRCT 19 (França)) ; Hernández Gutierrez, Alicia (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Martinez, Alejandra (INSERM CRCT 19 (França)) ; Universitat Autònoma de Barcelona
We sought to evaluate the impact on survival of tumor burden and surgical complexity in relation to the number of cycles of neoadjuvant chemotherapy (NACT) in patients with advanced ovarian cancer (OC) with minimal (CC-1) or no residual disease (CC-0). [...]
2021 - 10.3802/jgo.2021.32.e78
Journal of Gynecologic Oncology, Vol. 32 (august 2021)  
Registro completo - Creative Commons
20.
11 p, 421.8 KB Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, Jonathan W. (David Geffen School of Medicine. University of California Los Angeles) ; John, Thomas (Department of Medical Oncology. Austin Health) ; Grohe, Christian (Klinik fur € Pneumologie-Evangelische Lungenklinik Berlin Buch) ; Laktionov, Konstantin (N.N. Blokhin National Medical Research Center of Oncology (Rússia)) ; Kim, Sang-We (Department of Oncology. Asan Medical Center) ; Kato, Terufumi (Depart-ment of Thoracic Oncology. Kanagawa Cancer Center) ; Vu, Huu Vinh (Department of Thoracic Surgery. Choray Hospital) ; Lu, Shun (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ; Li, Shanqing (Department of Thoracic Surgery. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences) ; Lee, Kye Young (Pre-cision Medicine Lung Cancer Center. Konkuk University Medical Center) ; Akewanlop, Charuwan (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ; Yu, Chong-Jen (Department of Internal Medicine. National Taiwan University Hospital Hsinchu Branch. National Taiwan University College of Medicine) ; De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ; Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto (IOV). IRCCS) ; Domine, Manuel (Hospital Universitario Fundacion Jimenez Díaz. Servicio de Oncología) ; Shepherd, Frances A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Cancer Center. the University of Toronto) ; Atagi, Shinji (Department of Thoracic Oncology. National Hospital Organization Kinki-Chuo Chest Medical Center) ; Zeng, Lingmin (Late Oncology Statistics. AstraZeneca) ; Kulkarni, Dakshayini (Late Oncology R&D. AstraZeneca) ; Medic, Nenad (AstraZeneca Oncology Business Unit. Academy House) ; Tsuboi, Masahiro (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ; Herbst, Roy S. (Medical Oncology. Yale School of Medicine. Yale Cancer Center) ; Wu, Yi-Long (Guangdong Lung Cancer Institute)
Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). [...]
2022 - 10.1158/1078-0432.CCR-21-3530
Clinical Cancer Research, Vol. 28 Núm. 11 (january 2022) , p. 2286-2296  
Registro completo - Creative Commons

Artículos : Encontrados 106 registros   anterior11 - 20siguientefinal  ir al registro:
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos